RESUMO

BACKGROUND: Brazil is the largest producer of coffee in the world. Studies on climate change estimate large impacts on the production of Coffea arabica (C. arabica). In this context, it is necessary to know the quantitative production values to provide evidence for policy makers to target the prompt answer. RESULTS: Using data from 18 municipalities located in five Brazilian states that produce more coffee in Brazil, in an unprecedented way, in this work it is shown that although the minimum temperature is the most important climatic variable for the production, its effect, although positive, and its degree of explanation, were technically too small to explain the volume of production in Brazilian conditions. According to the model of non-stationary time series ARIMA (1, 1, 0) coffee production in the future may reach almost four million tons, and the productivity almost 2500 kg ha-1 on average, with the advancement of technology as the main factor that should promote simultaneous increases in production and productivity. However, despite natural climate variations, which make it the most responsible for the variability of annual coffee production, the producer must increase the use of the technologies to support the Brazilian coffee agribusiness. CONCLUSIONS: The results of this study reveal that coffee production in Brazil is due much more to productivity than to the minimum ambient temperature change over the long term; despite this, the climate variable should be considered the most influential on the production and productivity of coffee. © 2017 Embrapa. Journal of the Science of Food and Agriculture © 2019 Society of Chemical Industry.

Assuntos

RESUMO

This study was conducted to investigate the activation ability of the platelet-rich plasma (PRP) by pharmacological agents, as well as to verify the need or not of this activation for therapeutic use. The PRP was obtained from four healthy crossbred geldings aged 13 to 16 years (15±1years), and was processed for observation and quantification of the platelet morphology by using the transmission electron microscopy. All PRP samples were activated with 10 percent calcium chloride (CaCl2) solution, pure bovine thrombin or associated with CaCl2. The control (pure PRP) was not pharmacologically activated. In the pure PRP samples, 49 percent of the platelets were classified as state of activation uncertain, 41 percent as resting, 9 percent as fully activated and 1 percent as irreversibly damaged. Treatment with 10 percent CaCl2 provided a distribution of 54 percent platelets in state of activation uncertain, 24 percent as fully activated, 20 percent as resting, and 2 percent as irreversibly damaged. The platelet morphology of the bovine thrombin treated samples did not fit into classification adopted, as showing irregular shape with emission of large filamentous pseudopods, appearance of ruptured and whole granules in the remaining cytoplasm and extracellular environment. There was effect of the treatment on the platelet morphology (P=0.03). The 10 percent CaCl2 is an adequate platelet-activating agent. However, in cases the use of PRP under its liquid form is necessary, the use of pure PRP is recommended, since besides presenting an adequate percentage of fully activated platelets it also has significant amount of the resting type, which can be activated by substances found in the injured tissue.

O objetivo desse estudo foi investigar a capacidade de ativação do plasma rico em plaquetas (PRP) por substâncias farmacológicas, assim como verificar a necessidade ou não dessa ativação para uso terapêutico. O PRP foi obtido de quatro equinos mestiços hígidos, machos castrados, com 13 a 16 anos (15±1anos) de idade, e processado para observação e quantificação da morfologia plaquetária mediante a utilização da microscopia eletrônica de transmissão. Todas as amostras de PRP foram ativadas com cloreto de cálcio (CaCl2) a 10 por cento, trombina bovina pura ou associada a CaCl2. O controle (PRP puro) não foi ativado farmacologicamente. Nas amostras de PRP puro, 49 por cento das plaquetas foram classificadas como ativação incerta, 41 por cento em repouso, 9 por cento totalmente ativada e 1 por cento com dano irreversível. O tratamento com CaCl2 a 10 por cento proporcionou uma distribuição de 54 por cento de plaquetas com ativação incerta, 24 por cento totalmente ativada, 20 por cento em repouso, e 2 por cento como com dano irreversível. Amostras tratadas com trombina bovina apresentaram morfologia plaquetária que não se enquadraram na classificação adotada, apresentando forma irregular com emissão de grandes pseudópodes filamentosos, aspecto de rompimento e grânulos inteiros no citoplasma remanescente e meio extracelular. Houve efeito do tratamento sobre a morfologia plaquetária (P=0,03). O CaCl2 a 10 por cento é um adequado agente ativador de plaquetas. Entretanto, nos casos onde se faz necessário o uso de PRP na forma mais líquida, recomenda-se o uso do PRP puro, que além de apresentar uma adequada porcentagem de plaquetas totalmente ativadas, também possui importante quantidade do tipo em repouso, que pode ser ativado por substâncias presentes no tecido lesionado.

Assuntos

RESUMO

This study was conducted to investigate the activation ability of the platelet-rich plasma (PRP) by pharmacological agents, as well as to verify the need or not of this activation for therapeutic use. The PRP was obtained from four healthy crossbred geldings aged 13 to 16 years (15±1years), and was processed for observation and quantification of the platelet morphology by using the transmission electron microscopy. All PRP samples were activated with 10 percent calcium chloride (CaCl2) solution, pure bovine thrombin or associated with CaCl2. The control (pure PRP) was not pharmacologically activated. In the pure PRP samples, 49 percent of the platelets were classified as state of activation uncertain, 41 percent as resting, 9 percent as fully activated and 1 percent as irreversibly damaged. Treatment with 10 percent CaCl2 provided a distribution of 54 percent platelets in state of activation uncertain, 24 percent as fully activated, 20 percent as resting, and 2 percent as irreversibly damaged. The platelet morphology of the bovine thrombin treated samples did not fit into classification adopted, as showing irregular shape with emission of large filamentous pseudopods, appearance of ruptured and whole granules in the remaining cytoplasm and extracellular environment. There was effect of the treatment on the platelet morphology (P=0.03). The 10 percent CaCl2 is an adequate platelet-activating agent. However, in cases the use of PRP under its liquid form is necessary, the use of pure PRP is recommended, since besides presenting an adequate percentage of fully activated platelets it also has significant amount of the resting type, which can be activated by substances found in the injured tissue.(AU)

O objetivo desse estudo foi investigar a capacidade de ativação do plasma rico em plaquetas (PRP) por substâncias farmacológicas, assim como verificar a necessidade ou não dessa ativação para uso terapêutico. O PRP foi obtido de quatro equinos mestiços hígidos, machos castrados, com 13 a 16 anos (15±1anos) de idade, e processado para observação e quantificação da morfologia plaquetária mediante a utilização da microscopia eletrônica de transmissão. Todas as amostras de PRP foram ativadas com cloreto de cálcio (CaCl2) a 10 por cento, trombina bovina pura ou associada a CaCl2. O controle (PRP puro) não foi ativado farmacologicamente. Nas amostras de PRP puro, 49 por cento das plaquetas foram classificadas como ativação incerta, 41 por cento em repouso, 9 por cento totalmente ativada e 1 por cento com dano irreversível. O tratamento com CaCl2 a 10 por cento proporcionou uma distribuição de 54 por cento de plaquetas com ativação incerta, 24 por cento totalmente ativada, 20 por cento em repouso, e 2 por cento como com dano irreversível. Amostras tratadas com trombina bovina apresentaram morfologia plaquetária que não se enquadraram na classificação adotada, apresentando forma irregular com emissão de grandes pseudópodes filamentosos, aspecto de rompimento e grânulos inteiros no citoplasma remanescente e meio extracelular. Houve efeito do tratamento sobre a morfologia plaquetária (P=0,03). O CaCl2 a 10 por cento é um adequado agente ativador de plaquetas. Entretanto, nos casos onde se faz necessário o uso de PRP na forma mais líquida, recomenda-se o uso do PRP puro, que além de apresentar uma adequada porcentagem de plaquetas totalmente ativadas, também possui importante quantidade do tipo em repouso, que pode ser ativado por substâncias presentes no tecido lesionado.(AU)

Assuntos